MindBio Therapeutics Corp.
MBIO
CNSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 163.92% | -69.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 186.99% | 22.45% | |||
| Operating Income | -186.99% | 89.67% | |||
| Income Before Tax | -725.08% | 82.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -725.08% | 82.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 800.00% | -- | |||
| Net Income | -705.21% | 82.39% | |||
| EBIT | -186.99% | 89.67% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -800.00% | 84.62% | |||
| Normalized Basic EPS | -1,000.00% | 87.50% | |||
| EPS Diluted | -800.00% | 84.62% | |||
| Normalized Diluted EPS | -1,000.00% | 87.50% | |||
| Average Basic Shares Outstanding | 0.88% | -2.21% | |||
| Average Diluted Shares Outstanding | 0.88% | -2.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
